Eyeing commercialization, a Shanghai-based CAR-T startup nabs a $186M megaround
Three years after its last financing and with six programs now in the clinic, Shanghai-based CARsgen therapeutics has raised $186 million to push forward a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
